Prostate Cancer

Alcohol Consumption and the Risk of Prostate Cancer: A Dose-Response Meta-Analysis.

Alcohol is widely consumed and is known as a major risk factor for several types of cancers. Yet, it is unclear whether alcohol consumption is associated with the risk of prostate cancer (PCa) or not.

Assessing Apps for Patients with Genitourinary Tumors Using the Mobile Application Rating Scale (MARS): Systematic Search in App Stores and Content Analysis.

The large number of available cancer apps and their impact on the population necessitates a transparent, objective, and comprehensive evaluation by app experts, health care professionals, and users.

[It is unclear whether pelvic lymphadenectomy is of oncological benefit in prostate cancer].

Fossati's 2017 review questions the value of pelvic lymphadenectomy (pLA) in radical prostatectomy (RP) because available studies fail to show any oncological benefit. Our finding that no spread of metastatic lymph nodes (LN) has been demonstrated is based on registry data, clinical trials without evidence of pLA benefit and considerations of the genetic link between LN metastasis and distant metastases.

Inguino-scrotal bladder hernia: an unexpected finding on 68Ga-PSMA-11 PET/CT.

Bladder herniation is an uncommon condition mimicking suspicious metastasis on PET/CT imaging. We report a 67 y/o man with prostate cancer referred for recurrence evaluation with 68Ga-PSMA-11 PET/CT.

PET Imaging Agents (FES, FFNP, and FDHT) for Estrogen, Androgen, and Progesterone Receptors to Improve Management of Breast and Prostate Cancers by Functional Imaging.

Many breast and prostate cancers are driven by the action of steroid hormones on their cognate receptors in primary tumors and in metastases, and endocrine therapies that inhibit hormone production or block the action of these receptors provide clinical benefit to many but not all of these cancer patients.

18F-Fluciclovine Positron Emission Tomography in Men with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiotherapy: Results from LOCATE - Beyond the Abstract

Biochemical recurrence after definitive therapy for prostate cancer is often faced by urologic oncologists and radiation oncologists. Historically, these patients may undergo workup with conventional imaging including computed tomography (CT), magnetic resonance imaging (MRI), and/or bone scans. However, these imaging modalities have limited sensitivity at lower prostate-specific antigens (PSA). More recently, advances in prostate cancer-specific positron emission tomography (PET) radiotracers have established new understandings of disease recurrence patterns. One of these radiotracers is 18F-fluciclovine, which is a synthetic amino acid that is preferentially taken up by prostate cancer cells - making it an attractive target as a radiotracer. 18F-Fluciclovine PET scans were FDA-approved for biochemically recurrent prostate cancer in 2016 and incorporated into the National Comprehensive Cancer Network (NCCN) guidelines in 2018.1

Antibody Selection Influences the Detection of AR-V7 in Primary Prostate Cancer - Beyond the Abstract

The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) is difficult to navigate since predictive markers for routine use are missing. The finding that the androgen receptor (AR) splice variant 7 (AR-V7) can help to identify patients who may not benefit from next-generation anti-androgens was hence met with great enthusiasm.1 However, as always in biology, there is no black and white, and therapeutic responses were subsequently found to have a somewhat less stringent correlation with AR-V7 than initially thought.2 Nevertheless, the detection of AR-V7 in blood, circulating tumor cells or in tumor tissue is an important emerging technique that holds the promise to optimize and personalize the therapy of patients with mCRPC.3

Can fewer transperineal systematic biopsy cores have the same prostate cancer detection rate as of magnetic resonance imaging/ultrasound fusion biopsy?

Due to the discomfort and incidence of complications increases with the increasing number of biopsy cores, the protocol of prostate biopsy has been promoted from systematic biopsy (SB) to targeted biopsy (TB) in many studies.

Automated [18F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination.

[18F]PSMA-1007, a positron emission tomography (PET) tracer, specifically targets prostate-specific membrane antigen (PSMA), which is highly expressed in prostate cancer. PSMA-PET is effective especially for regional detection of biochemical recurrence, which significantly affects patient management.

PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model.

While chimeric antigen receptor (CAR) T cell immunotherapy targeting CD19 has shown remarkable success in patients with lymphoid malignancies, the potency of CAR T cells in solid tumors is low so far.

The FGF/FGFR System in the Physiopathology of the Prostate Gland.

Fibroblast Growth Factors (FGFs) are a family of proteins possessing paracrine, autocrine or endocrine functions in a variety of biological processes, including embryonic development, angiogenesis, tissue homeostasis, wound repair, and cancer.

Moving away from systematic biopsies: image-guided prostate biopsy (in-bore biopsy, cognitive fusion biopsy, MRUS fusion biopsy) -literature review.

To compare the detection rate of clinically significant cancer (CSCa) by magnetic resonance imaging-targeted biopsy (MRI-TB) with that by standard systematic biopsy (SB) and to evaluate the role of MRI-TB as a replacement from SB in men at clinical risk of prostate cancer.

Toxicity of pelvic lymph node irradiation with intensity modulated radiation therapy for high-risk and locally advanced prostate cancer: a national population-based study using patient-reported outcomes.

Little is known about the toxicity of additional pelvic lymph node irradiation in men receiving intensity-modulated radiotherapy (IMRT) for prostate cancer. The aim of this study was to compare patient-reported outcomes following IMRT to the prostate only (PO-IMRT) versus the prostate and pelvic lymph nodes (PPLN-IMRT).

Implication of Prophetic Variables and Their Impulsive Interplay in CA Prostate Patients Experiencing Osteo-Metastasis.

To identify variables having a critical role in prostate cancer patients experiencing osteo-metastasis.

Prostatic carcinoma is a multifactorial complex disorder that exhibits increased propensity to develop bone metastasis.

Is prostate brachytherapy a dying art? Trends and variation in the definitive management of prostate cancer in ontario, canada.

Declining prostate brachytherapy utilization has been reported in several studies, despite strong evidence for efficacy and safety compared to alternatives. We sought to evaluate contemporary trends in brachytherapy, external beam radiotherapy (EBRT) and prostatectomy utilization in a publicly funded healthcare system.

AR-V7 as a biomarker for resistance to treatment with abiraterone/enzalutamide in three Latin American countries: a hypothetical cost-saving analysis.

Prostate cancer is the most incident and one of the deadliest male cancers in Latin America. Treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) includes androgen receptor signaling inhibitors (ARSi) such as abiraterone and enzalutamide, for which AR-V7, an androgen receptor splice variant, has emerged as a biomarker for primary resistance.

Radiotherapy of Prostate Carcinoma: A Comparison of the Predictive Role of EAU Versus NCCN Risk Stratification Systems.

To compare the predictive efficacy of National Comprehensive Cancer Network (NCCN) and European Association of Urology (EAU) risk stratification systems in radiotherapy of prostate cancer.

One-thousand-nine-hundred-nine patients treated with definitive (1,074), adjuvant (381), and salvage radiotherapy (454) were analysed.

Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer.

The tolerability of 2-weekly docetaxel at 25-35 mg/m2 for castration-resistant prostate cancer (CRPC) has not been fully evaluated. The aim of this study was to evaluate its tolerability compared to 3-weekly docetaxel at 60-75 mg/m2 in patients with CRPC.

Gain-loss framing and patients' decisions: a linguistic examination of information framing in physician-patient conversations.

When discussing risks and benefits with cancer patients, physicians could focus on losses such as mortality rates and cancer recurrence or, alternatively, gains such as survival rates and curing cancer.

Predictors of ISUP score upgrade in patients with low-risk prostate cancer.

The literature contains few studies that focus on the relationship between International Society of Urological Pathology (ISUP) score upgrade and complete blood count (CBC) parameters for patients with low-risk prostate cancer and studies achieved inconclusive results.